WeVote
Log In

Bill

Bill

A 3236

Enacts the "New York affordable drug manufacturing act"

2025 Regular Session Introduced by William Colton and 8 co-sponsors

Summary of New York Affordable Drug Manufacturing Act (A 3236) OverviewThe "New York Affordable Drug Manufacturing Act" (A 3236) aims to address the high cost of prescription drugs

REFERRED TO HEALTH
0
WeVote Research Nonpartisan
Bill Summary · A 3236

Summary of New York Affordable Drug Manufacturing Act (A 3236)

Overview

The "New York Affordable Drug Manufacturing Act" (A 3236) aims to address the high cost of prescription drugs in New York by establishing a state-run pharmaceutical manufacturing program. The bill seeks to leverage the state's purchasing power to produce and distribute generic versions of essential medications at affordable prices.

Key Provisions

  • Establishes the "New York Affordable Drug Manufacturing Program" within the state Department of Health
  • Directs the program to identify and manufacture generic versions of prescription drugs that are in high demand but face limited competition
  • Allows the state to partner with other states, local governments, and non-profit organizations to expand production and distribution
  • Requires the program to set prices for the generic drugs at no more than 80% of the average wholesale price
  • Creates a dedicated "Affordable Drug Manufacturing Fund" to support the program's operations, financed through appropriations and revenue from drug sales

Affected Stakeholders

  • New York residents who struggle to afford necessary prescription medications
  • Health care providers and facilities that serve low-income and uninsured patients
  • Private pharmaceutical companies that currently dominate the generic drug market
  • State and local governments seeking to reduce Medicaid and other health care costs

Timeline and Next Steps

The bill was referred to the state Assembly Health Committee on January 27, 2025 for initial consideration. If passed by the committee, it would then move to a full vote in the Assembly. A companion bill (S 1618) has also been introduced in the state Senate.

The bill's sponsors aim to have the manufacturing program operational within 18 months of the legislation's enactment. However, the timeline may be affected by budgetary negotiations, regulatory approvals, and potential legal challenges from the pharmaceutical industry.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.